Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): European Innovation Council Eurostars Background Cardiac gene transfer utilizing adeno-associated virus (AAV) is a promising approach for the treatment of various cardiovascular diseases. Intramyocardial injection is an efficient delivery route, and is particularly relevant for ischemic disease or pacemaker and conduction system abnormalities, where local treatment is favoured. However, which AAV variants provide efficient cardiac gene transfer after intramyocardial injection remains to be tested. Aim This study aims to compare several cardiotropic AAV variants in order to identify their relative potency in the setting of direct intramyocardial injection. Methods A green fluorescent protein (GFP)-coding sequence was packaged in the two benchmark AAV capsids, AAV6 and AAV9, and a selection of recently reported AAV9 capsid variants which are named MyoAAVs. These AAV vectors were added to neonatal rat ventricular cardiomyocytes (NRVM) and their transduction efficiency was evaluated by flow cytometry and quantitative PCR. AAV6, AAV9 and MyoAAV4A vectors were then delivered into the left ventricle of FVB mice via intramyocardial injection. AAV6 and AAV9 carrying GFP in a different expression cassette were also intramyocardially injected in FVB and Bl6 mice. Direct fluorescence, transgene mRNA, and viral genomes were quantified to determine the transduction efficiency 4 weeks post injection. Picrosirius red staining was used to assess whether AAV-mediated GFP delivery causes cardiac fibrosis. We further studied GFP encoding AAV6 and AAV9 vectors upon intramyocardial injection into the left ventricle of pigs and determined the transduction efficiency by quantitative PCR. Results NRVM transduction experiment revealed that among the tested capsid variants, AAV6 is the most efficient in transducing cardiomyocytes, followed by MyoAAV4A. In mice, AAV6 is most effective in transducing myocardium upon intramyocardial injection, resulting in approximately 10-fold higher transgene expression than that obtained with AAV9 vector and 2-fold higher than that with MyoAAV4A vector. Histology revealed no vector-related cardiac fibrosis. The use of different expression cassettes and animal strains consistently showed that AAV6 outperforms AAV9 in cardiac transduction efficiency. Transgene expression in liver was only observed in Bl6 mice injected with AAV9. In porcine myocardium, AAV6 led to robust transgene expression after intramyocardial injection and this expression level is higher than that of AAV9. Conclusion Among the AAV variants tested, AAV6 appears to be the most efficient for cardiac transduction by intramyocardial injection. These results suggest that AAV6 represents an attractive vector for direct cardiac gene transfer and for future capsid engineering in the context of local transgene delivery.

GW26-e2201 Recombinant Adeno-Associated Virus Serotype 9 Transfection of Atherosclerosis Mice: Determination of the Optimal Expression Time in Vivo

Construction of the Adeno-Associated Virus Enhanced Plasmid of Murine IL-10 and Its Expression in Murine Cardiomycocytes

Raav-Mediated Angiogenin Gene Transfer Induces Angiogenesis and Modifies Left Ventricular Remodeling in Rats with Myocardial Infarction

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

[Recombinant Adeno-Associated Virus Type 8 Mediated Dual-Luciferase Gene Expression in Mouse].

Targeting transgene to the heart and liver with AAV9 by different promoters

Recombinant Adeno-Associated Viral Vector 2-Mediated Gene Transfer of VEGF165 Improved Porcine Chronic Myocardial Ischemia

Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 9 in a symptomatic mouse model

AAV9-Retro mediates efficient transduction with axon terminal absorption and blood–brain barrier transportation

Preparation of Raav9 to Overexpress or Knockdown Genes in Mouse Hearts

637. Recombinant Adeno-Associated Viral Vector 2-Mediated Gene Transfer of VEGF Induces Neovascular Formation and Improves Blood Flow in Chronic Ischemic Swine Myocardium

Enhancing transduction of the liver by adeno-associated viral vectors

Optimization of adeno-associated virus (AAV) gene delivery into human bone marrow stem cells (hBMSCs)

Adeno-associated virus (AAV) 6 provides efficient gene transfer upon intramyocardial injection in vivo

AAV Gene Transfer to the Heart

Construction and Identification of Recombinant Adeno- Associated Virus Vector Co-Expressing Human Vascular Endothelial Growth Factor and Green Fluorescent Protein

An efficient AAV vector system of Rec2 serotype for intravenous injection to study metabolism in brown adipocytes in vivo

Construction of a gengeral adeno-associated virus vector and GFP expression in rat NIH3T3 transduced by the rAAV vector

The Safety Assessment of Gene Transfer Mediated by the New Recombinant Adeno-Associated Virus Serotype 1 Pseudotyped Vector in Mouse Ischemic Lamb Model

Assessment of Adipocyte Transduction Using Different AAV Capsid Variants

Hardwiring tissue-specific AAV transduction in mice through engineered receptor expression